U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H30O5
Molecular Weight 374.4714
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLPREDNISOLONE

SMILES

C[C@@]1([H])C[C@@]2([H])[C@]3([H])CC[C@](C(=O)CO)([C@@]3(C)C[C@@]([H])([C@]2([H])[C@@]4(C)C=CC(=O)C=C14)O)O

InChI

InChIKey=VHRSUDSXCMQTMA-PJHHCJLFSA-N
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html

Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist.

Originator

Curator's Comment:: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.39999999999999991 nM [EC50]
1.07000000000000006 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MEDROL

Approved Use

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Launch Date

-384739200000
Primary
MEDROL

Approved Use

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Launch Date

-384739200000
Primary
MEDROL

Approved Use

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Launch Date

-384739200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
213 ng/mL
32 mg single, intravenous
dose: 32 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
931 ng × h/mL
32 mg single, intravenous
dose: 32 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
32 mg single, intravenous
dose: 32 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
23%
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg/kg single, intravenous
Highest studied dose
Dose: 1000 mg/kg
Route: intravenous
Route: single
Dose: 1000 mg/kg
Sources:
unhealthy, 0-15 years
Health Status: unhealthy
Age Group: 0-15 years
Sex: M+F
Sources:
1250 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1250 mg, 1 times / day
Sources:
unhealthy, 18–59 years
Health Status: unhealthy
Age Group: 18–59 years
Sex: M+F
Sources:
120 mg 1 times / week multiple, intramuscular
Highest studied dose
Dose: 120 mg, 1 times / week
Route: intramuscular
Route: multiple
Dose: 120 mg, 1 times / week
Sources:
unhealthy, adult
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.
1998 Jul
Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculous therapy with rifampicin.
1999 Jan
Pulse methylprednisolone therapy for arthritis causing muscle weakness.
1999 Sep
Use of epidural steroids after discectomy may predispose to infection.
2000 Feb 15
High-dose methylprednisolone may do more harm for spinal cord injury.
2000 Nov
Methylprednisolone concentrations in the vitreous and the serum after pulse therapy.
2001
The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8).
2001
Lupus nephritis in a child with AIDS.
2001 Apr
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
2001 Apr
Severe renal impairment in the case of classic polyarteritis nodosa.
2001 Feb
Selective involvement of the choroid plexus on cerebral magnetic resonance images: a new radiological sign in patients with systemic lupus erythematosus with neurological symptoms.
2001 Feb
Lupus nephritis in children: prognostic significance of clinicopathological findings.
2001 Feb
[Psychological and behavioral disorders with good outcome in neurosarcoidosis].
2001 Feb
[Value of abdominal-pelvic computed tomography in adult rheumatoid purpura].
2001 Feb
Monocyte-derived dendritic cells: a potential target for therapy in multiple sclerosis (MS).
2001 Feb
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
2001 Feb
Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation.
2001 Feb-Mar
Prevention of bone loss in kidney graft recipients.
2001 Feb-Mar
Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue.
2001 Jan
[Severe chronic actinic dermatitis treated with cyclosporine: 2 cases].
2001 Jan
Two cases of severe bronchopneumonia due to influenza A (H3N2) virus: detection of influenza virus gene using reverse transcription polymerase chain reaction.
2001 Jan
Preventive effects of lecithinized superoxide dismutase and methylprednisolone on spinal cord injury in rats: transcriptional regulation of inflammatory and neurotrophic genes.
2001 Jan
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes.
2001 Jan
Severe arthralgia and myalgia due to high-dose methylprednisolone pulse therapy cured by potassium infusion in a patient with diffuse proliferative lupus nephritis.
2001 Jan
High-dose methylprednisolone treatment in experimental focal cerebral ischemia.
2001 Jan
The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease.
2001 Jan
Methylprednisolone ameliorates cochlear nerve degeneration following mechanical injury.
2001 Jan
Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma.
2001 Jan
Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection.
2001 Jan 27
Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy.
2001 Jan-Feb
[Value of methylprednisolone perfusions in the corticodependent forms of Horton's disease].
2001 Mar
Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes.
2001 Mar
Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
2001 Mar
Intrathecal methylprednisolone for postherpetic neuralgia.
2001 Mar 29
Intrathecal methylprednisolone for postherpetic neuralgia.
2001 Mar 29
Patents

Sample Use Guides

In Vivo Use Guide
Each Medrol Tablet (methylprednisolone) for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone. The initial dosage of Medrol Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated.
Route of Administration: Other
Treatment with methylprednisolone concentrations above 50 uM could ignificantly reduce the proliferation activity of human CLL cell line MEC-1 by 23.34%, 30.73%, 30.57% after 24 h, and 28.48%, 42.35%, 44.56% after 48 h respectively
Name Type Language
METHYLPREDNISOLONE
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
U-67,590A
Code English
METHYLPREDNISOLONE [USP]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 11,17,21-TRIHYDROXY-6-METHYL-, (6.ALPHA.,11.BETA.)-
Systematic Name English
METHYLPREDNISOLONE [GREEN BOOK]
Common Name English
METHYLPREDNISOLONE [EP MONOGRAPH]
Common Name English
NSC-19987
Code English
METHYLPREDNISOLONE [MI]
Common Name English
11.BETA.,17,21-TRIHYDROXY-6.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
METHYLPREDNISOLONE [MART.]
Common Name English
6-METHYL-PREDNISOLONE
Common Name English
METHYLPREDNISOLONE COMPONENT OF NEO-MEDROL
Common Name English
METHYLPREDNISOLONE [USP-RS]
Common Name English
METHYLPREDNISOLONE [ORANGE BOOK]
Common Name English
METHYLPREDNISOLONE [INN]
Common Name English
NEO-MEDROL COMPONENT METHYLPREDNISOLONE
Common Name English
J3.872E
Code English
METHYLPREDNISOLONE [JAN]
Common Name English
METHYLPREDNISOLONE [WHO-DD]
Common Name English
MEDROL
Brand Name English
6-METHYLPREDNISOLONE
Common Name English
METHYLPREDNISOLONE [VANDF]
Common Name English
METHYLPREDNISOLONE [HSDB]
Common Name English
Classification Tree Code System Code
WHO-VATC QH02AB04
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
FDA ORPHAN DRUG 531816
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC S01CA08
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
CFR 21 CFR 520.1408
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC D07AA01
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
CFR 21 CFR 520.1409
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QD07CA02
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QH02BX01
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
CFR 21 CFR 522.1410
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC H02BX01
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QS01CA08
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC D07CA02
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC D07AC14
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QD10AA02
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QD07AA01
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC H02AB04
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
NDF-RT N0000175450
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC D10AA02
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
LIVERTOX 626
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1768
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
MESH
D008775
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
NCI_THESAURUS
C647
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
DRUG BANK
DB00959
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
HSDB
3127
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
CAS
83-43-2
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
INN
732
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
PUBCHEM
6741
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
USP_CATALOG
1435003
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY USP-RS
IUPHAR
7088
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
EPA CompTox
83-43-2
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
RXCUI
6902
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY RxNorm
EVMPD
SUB08872MIG
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
LACTMED
Methylprednisolone
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
FDA UNII
X4W7ZR7023
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
ECHA (EC/EINECS)
201-476-4
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
ChEMBL
CHEMBL650
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
WIKIPEDIA
METHYLPREDNISOLONE
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
MERCK INDEX
M7454
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY Merck Index